+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Filgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446137
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Amgen Inc.
  • Biocon
  • Claris Life Sciences
  • F. Hoffmann-La Roche Ltd.
  • Intas Biopharmaceuticals
Filgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global filgrastim biosimilars market.







This report focuses on the filgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the filgrastim biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for filgrastim biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Filgrastim Biosimilars market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider filgrastim biosimilars market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The filgrastim biosimilars market section of the report gives context. It compares the filgrastim biosimilars market with other segments of the filgrastim biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, filgrastim biosimilars market indicators comparison.

Scope


Markets Covered:


  • By Application: Oncology; Chronic and Autoimmune Diseases; Blood Disorders; Growth Hormone Deficiency; Infectious Diseases; Others
  • By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • By Type Of Manufacturing: In-House Manufacturing; Contract Manufacturing Oraganization

Companies Mentioned:


Cadila Pharmaceuticals; Dr. Reddy's Laboratories; Intas Biopharmaceuticals; Sandoz; Amgen Inc.

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Filgrastim Biosimilars Market

What is the estimated value of the Global Filgrastim Biosimilars Market?

The Global Filgrastim Biosimilars Market was estimated to be valued at $0.8 billion in 2021.

What is the growth rate of the Global Filgrastim Biosimilars Market?

The growth rate of the Global Filgrastim Biosimilars Market is 7.8%, with an estimated value of $1.0 billion by 2025.

What is the forecasted size of the Global Filgrastim Biosimilars Market?

The Global Filgrastim Biosimilars Market is estimated to be worth $1.0 billion by 2025.

Who are the key companies in the Global Filgrastim Biosimilars Market?

Key companies in the Global Filgrastim Biosimilars Market include Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Claris Life Sciences.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Amgen Inc.
  • Biocon
  • Claris Life Sciences
  • F. Hoffmann-La Roche Ltd.
  • Intas Biopharmaceuticals

1. Executive Summary2. Filgrastim Biosimilars Market Characteristics3. Filgrastim Biosimilars Market Trends and Strategies4. Impact Of COVID-19 On Filgrastim Biosimilars
5. Filgrastim Biosimilars Market Size and Growth
5.1. Global Filgrastim Biosimilars Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Filgrastim Biosimilars Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Filgrastim Biosimilars Market Segmentation
6.1. Global Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oncology
  • Chronic and Autoimmune Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Others
6.2. Global Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
6.3. Global Filgrastim Biosimilars Market, Segmentation by Type of Manufacturing, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • In-House Manufacturing
  • Contract Manufacturing Oraganization

7. Filgrastim Biosimilars Market Regional and Country Analysis
7.1. Global Filgrastim Biosimilars Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Filgrastim Biosimilars Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Filgrastim Biosimilars Market
8.1. Asia-Pacific Filgrastim Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Filgrastim Biosimilars Market
9.1. China Filgrastim Biosimilars Market Overview
9.2. China Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Filgrastim Biosimilars Market
10.1. India Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Filgrastim Biosimilars Market
11.1. Japan Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Filgrastim Biosimilars Market
12.1. Australia Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Filgrastim Biosimilars Market
13.1. Indonesia Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Filgrastim Biosimilars Market
14.1. South Korea Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Filgrastim Biosimilars Market
15.1. Western Europe Filgrastim Biosimilars Market Overview
15.2. Western Europe Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Filgrastim Biosimilars Market
16.1. UK Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Filgrastim Biosimilars Market
17.1. Germany Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Filgrastim Biosimilars Market
18.4. France Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Filgrastim Biosimilars Market
19.1. Eastern Europe Filgrastim Biosimilars Market Overview
19.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Filgrastim Biosimilars Market
20.1. Russia Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Filgrastim Biosimilars Market
21.1. North America Filgrastim Biosimilars Market Overview
21.2. North America Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Filgrastim Biosimilars Market
22.1. USA Filgrastim Biosimilars Market Overview
22.2. USA Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Filgrastim Biosimilars Market
23.1. South America Filgrastim Biosimilars Market Overview
23.2. South America Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Filgrastim Biosimilars Market
24.1. Brazil Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Filgrastim Biosimilars Market
25.1. Middle East Filgrastim Biosimilars Market Overview
25.2. Middle East Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Filgrastim Biosimilars Market
26.1. Africa Filgrastim Biosimilars Market Overview
26.2. Africa Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Filgrastim Biosimilars Market, Segmentation by Distribution Channels, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Filgrastim Biosimilars Market Competitive Landscape and Company Profiles
27.1. Filgrastim Biosimilars Market Competitive Landscape
27.2. Filgrastim Biosimilars Market Company Profiles
27.2.1. Cadila Pharmaceuticals
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Dr. Reddy's Laboratories
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Intas Biopharmaceuticals
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Sandoz
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Amgen Inc.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Filgrastim Biosimilars Pipeline Analysis29. Key Mergers and Acquisitions in the Filgrastim Biosimilars Market30. Filgrastim Biosimilars Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Amgen Inc.
  • Biocon
  • Claris Life Sciences
  • F. Hoffmann-La Roche Ltd.
  • Intas Biopharmaceuticals
Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, and Aryogen Biopharma.

The global filgrastim biosimilars market is expected to grow from $0.72 billion in 2020 to $0.77 billion in 2021 at a compound annual growth rate (CAGR) of 6.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.04 billion in 2025 at a CAGR of 8%.

The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. Only goods and services traded between entities or sold to end consumers are included.

The filgrastim biosimilar market covered in this report is segmented by application into oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, others and by distribution channels into hospital pharmacy, retail pharmacy, online pharmacy.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the filgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. For instance, Sandoz got an USFDA approval for its 1st biosimilar ZarxioTM (filgrastim-sndz) of original biologic Neupogen®. The consent depended on a comprehensive package of analytical, nonclinical, and clinical information, which verified that Zarxio is highly similar to the US-licensed reference product. To get this approval Sandoz even had to fight a legal battle with Amgen who claims that Sandoz has infringed its manufacturing process. These kind of hurdles can restrict the growth of the filgrastim biosimilar market.

In January 2019, Kashiv Pharma, US-based biopharmaceuticals Research Company, acquired Adello biologics for an undisclosed amount. The new company will be known as Kashiv Biosciences. The deal will help Kashiv BioSciences in expanding its business offering in including drug delivery platforms consolidating delayed-release technology and gastric retention systems that improve the efficacy and safety of known drugs, the pipeline of seven development products targeting unmet clinical needs. Adello Biologics was founded in 2012 and is a biotechnology company that works on developing biosimilars including filgrastims. The company is headquartered in Piscataway, New Jersey.

Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilars. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, in July 2018 to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and in 2018 they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supported the growth of the filgrastim biosimilars market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in November 2018, biosimilar developer Alvotech and Fuji Pharma entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan, including filgrastims.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Cadila Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Intas Biopharmaceuticals
  • Sandoz
  • Amgen Inc.
  • Intas Pharmaceuticals
  • Emcure Pharmaceuticals Ltd.
  • Biocon
  • Aryogen Biopharma
  • Claris Life Sciences
  • Adello Biologics
  • Hospira (Pfizer)
  • Gennova Biopharmaceuticals
  • Teva Pharmaceuticals Industries
  • F. Hoffmann-La Roche Ltd.
  • Lupin Limited
  • Abbott Laboratories Inc.
  • Reliance Life Sciences Pvt. Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...